Background and Aims: Lipid lowering therapies are the mainstay of secondary prevention after myocardial infarction (MI). However, non-adherence to statins is a major problem that leads to off-target LDL-C levels and higher rates of adverse cardiovascular events.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Atherosclerosis
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Published online: August 05, 2019EAS19-0838
© 2019 Published by Elsevier Inc.